Abstract 1142: Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1142
Abstract: KRAS is one of the most frequently mutated genes in cancer and was long considered undruggable until the recent discovery of inhibitors that bind the inactive (GDP-bound) form of KRASG12C. The most clinically advanced of… read more here.
Keywords: discovery fmc; 376 novel; fmc 376; inhibitor ... See more keywords